Skip to Content
Merck
  • Postoperative changes in amniotic membrane as a carrier for allogeneic cultured limbal epithelial transplantation.

Postoperative changes in amniotic membrane as a carrier for allogeneic cultured limbal epithelial transplantation.

American journal of ophthalmology (2014-08-20)
Xiaolin Qi, Junyi Wang, Dapeng Sun, Qingjun Zhou, Lixin Xie
ABSTRACT

To investigate the morphologic changes and outcomes of the amniotic membrane as a carrier for allogeneic cultivated limbal epithelial transplantation. Prospective, noncomparative, interventional study. A total of 16 eyes receiving allogeneic cultivated limbal epithelial transplantation with amniotic membrane as a carrier were enrolled. Morphologic changes in the amniotic membrane were observed by confocal microscopy and RTVue optical coherence tomography. The paired t test was employed to compare the mean best corrected visual acuity (BCVA) and corneal stromal thickness. Of the 16 eyes, 12 had stable ocular surfaces (group A), while the other 4 eyes had failed surgeries due to immune rejection (group B). Confocal microscopy showed residual amniotic membrane tissues in 8 eyes in group A at 1 year. However, the amniotic membrane was not detected in group B at 8-10 months. RTVue optical coherence tomography showed discontinuous amniotic membrane tissues in all eyes in group A at 1 year, while highly reflective opacity was seen in the corneal stroma in group B. There were no statistically significant differences in mean BCVA and corneal stromal thickness in group A at 1 month and 1 year after transplantation (P > 0.05), but the mean BCVA showed a statistically significant difference at 1 month and after the disappearance of the amniotic membrane in group B (P < 0.05). For eyes with stable ocular surfaces after cultivated limbal epithelial transplantation, the amniotic membrane can be present in the cornea for at least 1 year, with no impact on visual acuity or corneal stromal thickness. Chronic inflammation and neovascularization on the ocular surface may accelerate the disappearance of the amniotic membrane.

MATERIALS
Product Number
Brand
Product Description

Supelco
Hydrocortisone 21-hemisuccinate, analytical standard
Hydrocortisone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard
Oxybuprocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Glutamine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Glutamine
Supelco
L-Glutamine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Glutamine, BioUltra, ≥99.5% (NT)
SAFC
L-Glutamine
Sigma-Aldrich
L-Glutamine, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-Glutamine, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Benoxinate hydrochloride, meets USP testing specifications
Sigma-Aldrich
L-Glutamine, ReagentPlus®, ≥99% (HPLC)